Kala Bio Inc (NAS:KALA)
$ 6.72 -0.1375 (-2.01%) Market Cap: 30.98 Mil Enterprise Value: 19.45 Mil PE Ratio: 0 PB Ratio: 4.51 GF Score: 46/100

Q1 2022 Kala Pharmaceuticals Inc Earnings Call Transcript

May 16, 2022 / 12:00PM GMT
Release Date Price: $37.08 (+8.47%)
Operator

Good morning, and welcome to the Kala Pharmaceuticals Conference Call to review its First Quarter 2022 Financial Results. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals. Please proceed.

Jill S. Steier
Kala Pharmaceuticals, Inc. - Executive Director of IR & Corporate Communications

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chief Executive Officer; Todd Bazemore, President and Chief Operating Officer; Kim Brazzell, Head of R&D and Chief Medical Officer; Mary Reumuth, Chief Financial Officer; and Darius Kharabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call.

During this call, we will make certain comments about Kala's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot